B AC K G R O U N D
Minimal change disease (MCD) or minimal change nephropathy is the major cause of the nephrotic syndrome (NS) in children, whereas in adults MCD is found in 10-15% of cases with primary NS [1] [2] [3] . On kidney biopsy glomeruli appear normal on light microscopy and no immune deposits are found on immunofluorescence microscopy. The characteristic disease lesion, diffuse and generalized epithelial foot process effacement affecting glomerular albumin permeability, is only found on electron microscopy [4] . The underlying cause for MCD is unclear, but it is often preceded by an infection or allergic reaction [3] . It has been proposed that MCD reflects a disorder of T lymphocytes conducive to inducing a circulating factor of immune origin altering glomerular permeability [5] [6] [7] . Increased expression in urine and glomeruli of CD80, a transmembrane protein expressed on B-cells and antigen-presenting cells as well as a costimulatory molecule required for T-cell activation, has been linked to active disease [8, 9] .
Most patients respond with complete remission to glucocorticoid (GC) therapy. Relapses are, however, quite common and in 10-25% of cases frequent relapses occur. GC-dependence is seen in 25-30% and GC-resistance is also observed [3] . A number of second-line therapies have been used including cyclophosphamide, calcineurin inhibitors, azathioprin or mycophenolate mofetil [3, 10] .
Rituximab is a chimeric monoclonal antibody directed against CD20 positive B cells and is increasingly used in immune-mediated renal disease, in particular in ANCAassociated vasculitis [11] [12] [13] . A number of paediatric publications have reported the use of rituximab for MCD [14] [15] [16] . In the adult setting, there have been fewer case reports [17, 18] . Recently, Takei et al. [19] published a report on single-dose rituximab at two time-points in GC-dependent patients with a 12-month follow-up. However the long-term effect of this treatment option in MCD has not been known. We have previously published a case-series with limited follow-up and present here 16 adult cases with multirelapsing, GC-dependant or GCresistant MCD and their response to rituximab therapy with extended follow-up [20] .
PAT I E N T S
Sixteen patients, nine female and seven male patients, ranging from 19 to 73 years of age were followed at the Department of Renal Medicine at Karolinska University Hospital with an initial diagnosis of nephrosis. Kidney biopsy consistent with MCD had been performed in all the patients. Five of the patients were first diagnosed as children or adolescents. Because of multiple relapses, GC-dependence or treatment resistance a number of second-line therapies had been tried in 9 of 16 patients. GC resistance was defined as persistence of NS despite of 16 weeks of high-dose prednisolone treatment, whereas GC dependence was defined as recurrence of proteinuria during prednisolone taper as defined by Waldman et al. [3] who have studied the largest cohort of adult patients with MCD.
Thirteen patients were GC dependant, two patients multirelapsing and one GC resistant. Patient 16 had previously been multirelapsing, but developed GC-dependence 15 years after diagnosis.
Clinical data regarding gender, age at MCD diagnosis and rituximab treatment, number of relapses and previous treatments are summarized in Table 1 and the lowest GC dose  before relapse in Table 3 . First biopsy was performed at diagnosis in all but Patients 9 and 11 (Table 1 ). Patient 9 was biopsied after 6 years at 8 years of age and Patient 11 who had lived abroad was first biopsied at 18 years of age despite a history of recurrent nephrosis since the age of 5. Repeat biopsies were done in Patient 2 after 4 years, in Patient 5 after 2 years, in Patient 7 after 3 years and Patient 14 after 2.5 years. All the repeat biopsies were consistent with the original diagnosis of MCD.
A number of patients, 11 out of 16, had previous adverse events related to GC and or second-line therapy. This included premature menopause at 41 years of age after cyclophosphamide treatment followed by significant osteoporosis and several fractures ( 
The initial protocol for rituximab was 500 mg 2 weeks apart for the first nine patients with the exception of Patient 5 who received 1000 mg 2 weeks apart as previously described [20] . Patient 10 was given 375 mg/m 2 at three time-points, with a total dose of 1500 mg. Finally, in order to standardize treatment and to evaluate possible reductions in relapse rates with a higher dose, patients 11-13 and 15 were given a rituximab dose of 375 mg/m 2 once weekly for 4 weeks, whereas patients 14 and 16 preferred being treated with 1000 mg 2 weeks apart. Total rituximab exposure thus varied between 1000 and 2800 mg. Paracetamol, anti-histamines and hydrocortisone sodium succinate was given according to standard local procedure. Concomitant GC dose at the time of rituximab administration was in the range of 20-60 mg per day being the highest in patient 9 who remained severely nephrotic after 8 weeks of high doses of oral GC. Lowest GC dose before relapse in GC-dependant patients and GC dose prior to rituximab in all the patients are shown in Table 3 . Patient 15 was unwilling to use any oral GC because of previous mood disturbances but agreed to i.v. methylprednisolone given once weekly together with rituximab (Table 3 ). The total methylprednisolone dose in this patient was 1500 mg. Only patient 11 was on a GC-sparing drug, tacrolimus, at rituximab treatment.
All the patients were on ACE-inhibitors, ARBs or both prior to rituximab therapy with the exception of Patients 2, 9, 10 and 14. Drugs other than prednisone given at the moment of first rituximab treatment are reported in Table 1 . No patient was given pneumocystis jirovecii prophylaxis as we did not intend to treat the patients with significant GC doses for an extended period of time.
All B-lymphocyte analyses (CD20/CD19 positive B lymphocytes) were done at the local clinical immunology laboratory. CD 19 positivity, which is co-expressed with CD 20 on these cells, was measured as a marker of B-cell depletion. B-cell depletion under rituximab therapy was defined as <0.5% CD 19 positive B-cells (reference 9-24%).
A D V E R S E E V E N T S
Patients 8 and 13 had transient hypotension during the first rituximab infusion. Patient 9 had itchy and red eyes during the first infusion, which resolved with a second dose of anti-histamines. During the following infusion, the patient was given a higher dose of hydrocortisone sodium succinate and there was no allergic reaction. No infectious complications were recorded.
R E S U LT S
All the patients were nephrotic or near-nephrotic before treatment with the exception of Patients 7, 8 and 16 who were treated during early remission. Thirteen of the patients responded to therapy with complete remission with normalized plasma-albumin and total reduction of proteinuria ( Table 2 ). The mean time for established remission in the complete responders was 1.4 months (range 0.5-2 months) after rituximab treatment. All the patients were B-cell depleted prior to the second dose (Table 2) . Patients 6 and 14 reached partial remission with ∼a 70, and 50% reduction in proteinuria (defined as >50% reduction of proteinuria from baseline). The latter was among the older in the series and had in addition to MCD chronic changes upon kidney biopsy as evidenced by hypertensive blood vessels and hyperfiltration suggesting more chronic kidney pathology. Patient 5 had no response to therapy. In this case a repeat biopsy was done 2 years after diagnosis but had not shown any other pathologies than MCD. Creatinine levels were normal in all but Patients 8 and 14, and did not change significantly between rituximab treatment and 12-month followup ( Table 2) . Tapering of GC began after the second rituximab dose. All follow-up GC doses at 3, 6 and 12 months are shown in Table 3 . In Patient 6 who responded partially GC was tapered completely mainly due to glucose intolerance. GC doses after rituximab response were significantly lower at the 12-month follow-up than when relapses had occurred in the past (P < 0.001; non-parametric Wilcoxon two-sample rank-sum test, Figure 1 (SAS statistical software Version 9.2, SAS Institute, Inc., Cary, NC, USA). Tacrolimus was successfully discontinued in Patient 11 at 3 months after 5 years of treatment. Follow-up was 12-70 months (mean 38.8; median 44). Outcome and follow-up are summarized in Table 2 .
R E L A P S E A N D R E T R E AT M E N T
There were seven relapses (in patients 1, 2, 4, 6, 7, 9 and 14) after 9-28 months. Patient 1, at relapse at 20 months, had been GC free for 6 months, which had previously not been possible during the disease duration of 15 years. A second series of rituximab was given at relapse and the patient is currently in remission after 49 months with a GC dose of 5 mg. The relapse in Patient 2 was treated with a moderate GC dose and quickly tapered to 5 mg and is currently 54 months later in remission. Patients 4 and 9 were also treated with GC only, in Patient 9 relapse occurred after being off GC for a month. Patient 7 was retreated with rituximab twice, first 4 months after first relapse and then 2 months after second relapse. This patient is now on a repeat rituximab schedule once a year and No oral GC used, only methyl prednisolone i.v., total dose 1500 mg.
F I G U R E 1 . Lowest glucorticoid (GC mg) dose before relapse (baseline) and GC dose at 12 months.
has been in remission for the last 12 months. Patient 6, who was a partial responder, was considered having a relapse as she became significantly more proteinuric with a urine albumin to creatinine ratio of 346.5 mg/mmol and a plasma-albumin level of 20 g/L after 10 months when GC was fully tapered. Rituximab was repeated with a higher rituximab dose 2 months after relapse, 1000 mg twice while avoiding GC mainly due to glucose intolerance during previous treatment. After 5 months proteinuria had decreased by 50% and she went subsequently into remission 3 years after initial rituximab treatment and 22 months after a second rituximab series. Patient 14, a partial responder, was after 13 months significantly more proteinuric again with a urine albumin to creatinine ratio of 908.3 mg/ mmol and a plasma-albumin level of 14 g/L and has recently been retreated with rituximab. At the latest follow-up 66% of all responding patients were no longer on any immune suppressive therapy.
At relapse the CD 20/CD 19 count was 5, 9, 3, 1 and 2% in patients 1, 2, 6, 7 and 14, respectively. No data was available regarding B-cell repletion in Patients 4 and 9.
D I S C U S S I O N
This case-series is one of the largest of adults with a wide range of ages treated with rituximab as second-line therapy for biopsy-proven MCD with a history of multiple relapses, GCdependence and GC-resistance and with the longest followup. In 13 out of 16 patients, full remission was established after initial rituximab treatment. In the remaining cases partial remission was achieved in all but one patient who was the only patient with GC-resistance. In our experience rituximab performed well and safely as a GC-sparing agent by enabling discontinuation or tapering of GC significantly below levels where relapses had occurred in the past. In patients with extended follow-up for 24 months or more 4 out of 10 initial complete responders did not relapse. Of the relapsing patients, four have been retreated with rituximab and three with GC only again with favorable outcome. The latter were considered to have minor relapses and as they responded quickly with a moderate GC dose, rituximab was not deemed necessary. The cumulative number of patients with long-term remission (24 months) including treated relapses is now 8 out of 10 patients. These results are similar to a paediatric long-term follow-up study by Kemper et al., where 29 patients with 24 months data was available [16] . In the relapsing cases, the CD20/CD19 count was fairly similar to levels prior to first rituximab therapy suggesting that B-cell recovery may be used as a risk marker associated with relapse.
The range of rituximab dosing has varied greatly in various reports from a single dose, flat doses of 500 or 1000 mg given at one or two time-points to adherence to the B-cell lymphoma protocol, i.e. 375 mg/m 2 once weekly for 4 weeks [14] [15] [16] [17] [18] [19] [20] . Most of the case-series are from paediatric centres but with limited follow-up with the exception of the study by Kemper et al. with a median follow-up of 36 months [16] . Takei et al. treated 25 adult patients with GC-dependant MCD with a single 1000 mg rituximab dose administered twice at an interval of 6 months with a 12-month follow-up. Significant B-cells increases were seen in 10 patients before the second dose at 6 months and again in 5 at 12 months. Three patients developed relapse at 6 months and one at 12 months suggesting that B-cell restitution is not always associated with relapse [19] . In our study, the rituximab dose varied from 1000 to 2800 mg. Our initial protocol with a flat dose of 500 mg 2 weeks apart was encouraging with regard to remission occurrence. However, since some of the initial patients were experiencing relapses we increased initial rituximab exposure in subsequent patients to evaluate whether this had any bearing on relapses rather than response. Munyentwali et al., who were the first to describe efficacy of rituximab in a MCD case, recently reported an adult series of 17 rituximab GC-dependant or frequently relapsing MCD patients [17, 21] . They presented a slightly lower mean follow-up than in our study 26.7 months (range 5.1-82), but their results were very similar to ours with a high response rate. Six patients had at least one relapse and two of these patients had two and three relapses, respectively. The number of patients off any immunosuppressive treatment at last follow-up was 70%. Seven patients in their series were treated with significant proteinuria. Relapses usually occurred in the setting of B-cell recovery, but some patients did not relapse upon B-cell restitution as previously described [19] . Relapse rates were lower in patients treated with rituximab in remission compared with proteinuric patients. There has been a concern about possible loss of rituximab in the urine in nephrotic patients affecting efficacy [22] . In our patients, however, the relapsing patients had a median urine albumin creatinine ratio of 323.4 compared with the non-relapsers 258.4 (n.s.). The timing of rituximab treatment may still be an important point for future protocols.
It is difficult to draw any robust conclusions from ours and other results due to the limited number of patients treated. It may be that a higher or repeated dose is more beneficial for long-term remission at least for some of those who repeat their B-cells quickly. Fixed-interval rituximab re-treatment in relapsing cases may be an alternative as has been suggested in relapsing ANCA-vasculitis patients for a more prolonged period of remission [23] . Yet in our experience some patients given rituximab in the lower range remained relapse free over the long term. This was also observed by Munyentwali et al., who did not find any correlation between rituximab dose protocols and relapses [21] . However, as we have not measured CD20/CD19 consistently other than in relapsing cases we lack longitudinal data in this regard. Repeated treatment may play a role for achieving and maintaining remission over the long term such as in case 6 who went into remission 3 years after initial rituximab treatment and 22 months after a second series. This finding in a patient who had been proteinuric for 8 years may have been the result of a late response to rituximab. A spontaneous remission must also be taken into account. It may also be that repeated rituximabinduced changes in the immune system made the patient more resistant to disease. The safety profile of repeated rituximab in rheumatoid arthritis seems reassuring; however, the development of low immunoglobulin levels remains a concern [24] .
It is still not clear how B-cell depletion can induce remission in MCD. It has been proposed that the effect could be indirect by inhibiting B-cells who play an important role as immunoregulatory cells. Their removal could have a restraining effect on other immune cells such as T-lymphocytes, dendritic cells or macrophages [25] [26] [27] .
To conclude, our results and other reports suggest that Bcell depletion through rituximab therapy is well tolerated and induces remission in a large proportion of GC-dependent and multirelapsing MCD patients and is well established as a GCsparing agent in this disease. However, a number of issues need to be studied such as optimal rituximab dosage for first treatment, risk for relapses and subsequent treatment, which should be the focus of a randomized controlled trial. Rituximab may be useful as maintenance therapy in GC-dependent and multirelapsing MCD. However this should be addressed together with B-cell repletion surveillance and safety focusing on decreases in immunoglobulin levels and risk for infections.
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